Scienture Holdings (SCNX) Q4 2024 earnings summary

Executive summary

• Completed the acquisition of Scienture LLC, a specialty pharmaceutical company focused on CNS and CVS diseases, in July 2024, and changed the company name to Scienture Holdings, Inc.

• Disposed of non-core assets, including the sale of Softell's assets and the divestiture of Superlatus, resulting in significant gains from discontinued operations.

• Declared and paid special cash dividends totaling $14.9 million in 2024, funded by asset sales.

Financial highlights

• Revenue from continuing operations was $136,643 for 2024, down 90% year-over-year due to asset dispositions.

• Net loss from continuing operations was $18.2 million, compared to $8.5 million in 2023.

• Net income for 2024 was $9.1 million, driven by $27.3 million in income from discontinued operations.

• Cash at year-end was $308,096, with an accumulated deficit of $39.0 million.

• Operating expenses increased 231% to $14.7 million, mainly due to higher G&A, R&D, and professional fees.

• Research and development expenses were $2.2 million, allocated across four main product candidates.

Outlook and guidance

• Management expects operating expenses and working capital requirements of approximately $9.8 million for 2025.

• Plans to continue implementing the Scienture LLC business plan and pursue strategic transactions for non-core subsidiaries.

• Additional capital will be required to support ongoing operations and product development.